EcoDrugPlus

Somatostatin Receptor 4

Ensembl ID : ENSLCAG00010023753
Gene Symbol: SSTR4
4 Cross references
206 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSLCAG00010008021
Gene Symbol: SI:ZFOS-169G10.2
3 Cross references
182 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSLCAG00010023634
Gene Symbol: SPHK2
3 Cross references
200 Possible Orthologues:

Spleen Tyrosine Kinase

Ensembl ID : ENSLCAG00010011881
Gene Symbol: LOC108900733
4 Cross references
200 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2a

Ensembl ID : ENSLCAG00010015204
Gene Symbol: LOC108882308
4 Cross references
208 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2b

Ensembl ID : ENSLCAG00010005910
Gene Symbol: SRD5A2B
4 Cross references
191 Possible Orthologues:

Sterol O-Acyltransferase 1

Ensembl ID : ENSLCAG00010026917
Gene Symbol: LOC108881364
4 Cross references
210 Possible Orthologues:

Tachykinin Receptor 1

Ensembl ID : ENSLCAG00010027685
Gene Symbol: TACR1
4 Cross references
194 Possible Orthologues:

Tachykinin Receptor 1b

Ensembl ID : ENSLCAG00010020688
Gene Symbol: TACR1B
1 Cross references
193 Possible Orthologues:

Tachykinin Receptor 2

Ensembl ID : ENSLCAG00010026213
Gene Symbol: TACR2
4 Cross references
199 Possible Orthologues:

Tachykinin Receptor 3

Ensembl ID : ENSLCAG00010002224
Gene Symbol: TACR3
1 Cross references
208 Possible Orthologues:

Tachykinin Receptor 3-Like

Ensembl ID : ENSLCAG00010003513
Gene Symbol: TACR3L
2 Cross references
218 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).